Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of rapcabtagene autoleucel versus active comparator in severe treatment-refractory idiopathic inflammatory myopathies
MOH_2024-11-14_013736Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Nov 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rapcabtagene autoleucel in Autoimmune Myopathies, dermatomyositis (DM), antisynthetase syndrome (ASSD) and 1 more (2 arms), sponsored by Novartis. Started Nov 2024; status: recruiting.
02
Drugs
rapcabtagene autoleucel
03
Conditions
Autoimmune Myopathiesdermatomyositis (DM)antisynthetase syndrome (ASSD)immune-mediated necrotizing myopathy (IMNM)
Beyond the preview
Go deeper on MOH_2024-11-14_013736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-11-14_013736.